NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Grant supports planning & implementing clinical trials in dental research through UG3/UH3 cooperative agreement applications with NIDCR.
Funder: National Institutes of Health
Due Dates: November 9, 2026 (Resubmission) | February 8, 2027 (New) | March 8, 2027 (Resubmission) | June 7, 2027 (New) | July 7, 2027 (Resubmission) | October 7, 2027 (New) | November 8, 2027 (Resubmission) | January 6, 2028 (Final closing)
Funding Amounts: UG3: less than $400,000 in direct costs for one year; UH3: uncapped, needs-based budget for up to five years
Summary: Supports planning and implementation of investigator-initiated clinical trials testing drugs, biologics, devices, or procedures for dental, oral, or craniofacial conditions.
Key Information: Submit both phases in one application; UG3 funding does not guarantee transition to UH3 implementation.
Description
The National Institute of Dental and Craniofacial Research (NIDCR) supports investigator-initiated clinical trials through a phased UG3/UH3 cooperative agreement. Each award supports one trial testing a drug, biologic, device, or procedure to prevent, diagnose, or treat dental, oral, or craniofacial diseases or conditions. Trials may involve any phase of testing for an FDA-regulated product.
The one-year UG3 phase supports scientific and operational planning, including feasibility assessments and preparation of trial documents. The UH3 phase supports trial implementation for up to five years. NIDCR seeks well-designed, hypothesis-driven trials with clinically meaningful outcomes important to patients and health care providers. Examples include tissue regeneration, diagnostic technologies, surgical interventions, oral disease therapies, and orofacial pain management. Behavior-change intervention studies are not supported.
